Last reviewed · How we verify
FLOT scheme
FLOT is a chemotherapy combination regimen that uses multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis.
FLOT is a chemotherapy combination regimen that uses multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis. Used for Gastric cancer (neoadjuvant and palliative treatment), Gastroesophageal junction cancer.
At a glance
| Generic name | FLOT scheme |
|---|---|
| Sponsor | Fujian Medical University |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FLOT combines fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, and docetaxel to target rapidly dividing cancer cells through multiple mechanisms including thymidylate synthase inhibition, DNA cross-linking, and microtubule disruption. The combination is designed to provide synergistic anti-tumor activity with improved efficacy compared to single-agent chemotherapy.
Approved indications
- Gastric cancer (neoadjuvant and palliative treatment)
- Gastroesophageal junction cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Mucositis
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLOT scheme CI brief — competitive landscape report
- FLOT scheme updates RSS · CI watch RSS
- Fujian Medical University portfolio CI